Restricted Calorie Ketogenic Diet for the Treatment of Glioblastoma Multiforme

  title={Restricted Calorie Ketogenic Diet for the Treatment of Glioblastoma Multiforme},
  author={Joseph C. Maroon and Jeffrey W Bost and Austin Amos and Giulio Zuccoli},
  journal={Journal of Child Neurology},
  pages={1002 - 1008}
Glioblastoma multiforme is the most common malignant primary brain tumor in adults and generally considered to be universally fatal. Glioblastoma multiforme accounts for 12% to 15% of all intracranial neoplasms and affects 2 to 3 adults per every 100,000 in the United States annually. In children glioblastoma multiforme accounts for only approximately 7% to 9% of central nervous system tumors. The mean survival rate in adults after diagnosis ranges from 12 to 18 months with standard therapy and… 

The Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the Literature

Recent clinical findings have demonstrated that induced hypoglycemia and ketogenic diet are tolerable and can potentially be an adjuvant to standard treatments, such as surgery and chemoradiation.

Could Metabolic Therapy Become a Viable Alternative to the Standard of Care for Managing Glioblastoma

Studies in preclinical models show that calorie restricted ketogenic diets (KD-R), anti-glycolytic drugs, and hyperbaric oxygen therapy can reduce availability of glucose and glutamine in the tumor microenvironment while enhancing oxidative stress in tumor cells.

MR-Spectroscopy and Survival in Mice with High Grade Glioma Undergoing Unrestricted Ketogenic Diet

The accumulation of b HB in the tumor tissue in mice undergoing the KD, may suggest either elevated uptake/release of bHB by tumor cells, or the inability of tumor cells in this context to use it for mitochondrial metabolism.

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. The standard therapy for GBM is maximal surgical resection followed by radiotherapy with concurrent and adjuvant

Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report

The long-term survival of this patient, now at 80 months, could be due in part to a therapeutic metabolic synergy between KMT and the IDH1 mutation that simultaneously target the glycolysis and glutaminolysis pathways that are essential for GBM growth.

Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature

KD is safe and without major side effects; ketosis can be induced using customary foods; treatment with KD may be effective in controlling the progression of some gliomas; and further studies are needed to determine factors that influence the effectiveness of KD.

Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model

The data suggest that targeting the metabolic characteristics of neuroblastoma could open a new front in supporting standard therapy regimens, and it is proposed that a ketogenic diet and/or calorie restriction should be further evaluated as a possible adjuvant therapy for patients undergoing treatment for Neuroblastoma.



The Restricted Ketogenic Diet : An Alternative Treatment Strategy for Glioblastoma Multiforme a report

Information is provided on how the restricted ketogenic diet (RKD) might serve as an effective alternative to the current standard of care for controlling growth and enhancing survival in patients with GBM.

Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report

This is the first report of confirmed GBM treated with standard therapy together with a restricted ketogenic diet, and as rapid regression of GBM is rare in older patients following incomplete surgical resection and standard therapy alone, the response observed in this case could result in part from the action of the calorie restrictedketogenic diet.

Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports.

While this ketogenic diet does not replace conventional antineoplastic treatments, these preliminary results suggest a potential for clinical application which merits further research.

Canadian recommendations for the treatment of glioblastoma multiforme

Recommendation 1 Management of patients with glioblastoma multiforme (gbm) should be highly individualized and should take a multidisciplinary approach involving neuro-oncology, neurosurgery,

Ketogenic Diet for the Treatment of Refractory Epilepsy in Children: A Systematic Review of Efficacy

Although controlled trials are lacking, the evidence is sufficient to determine that the ketogenic diet is efficacious in reducing seizure frequency in children with refractory epilepsy.

Metabolic management of brain cancer.

Targeting energy metabolism in brain cancer: review and hypothesis

A radically different approach to brain cancer management is proposed that combines metabolic control analysis with the evolutionarily conserved capacity of normal cells to survive extreme shifts in physiological environment.

Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet

The results suggest that management of malignant astrocytoma with restricted ketogenic diets could be enhanced when combined with drugs that inhibit glycolysis.

Genetic alterations and signaling pathways in the evolution of gliomas

The current status of genetic alterations and signaling pathways operative in the evolution of astrocytic and oligodendroglial tumors is summarized.

Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial

Pilot data suggest that a ketogenic diet is suitable for even advanced cancer patients and has no severe side effects and might improve aspects of quality of life and blood parameters in some patients with advanced metastatic tumors.